NCT04232670: PERCePT

Pancreatic Endotherapy for Refractory Chronic Pancreatitis

Completed NA Results posted Last updated 24 September 2025

What this trial tests

NA trial testing EUS + SHAM in Pancreatic Duct Stone in 14 participants. Completed in 30 June 2024.

Timeline

9 October 2020

Primary endpoint
30 June 2024

30 June 2024

Quick facts

Lead sponsor	Oregon Health and Science University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	14
Start date	9 October 2020
Primary completion	30 June 2024
Estimated completion	30 June 2024
Sites	2 locations across United States

Drugs / interventions tested

• EUS + SHAM
• EUS + Pancreatic Endotherapy

Conditions studied

• Pancreatic Duct Stone — all drugs for Pancreatic Duct Stone →
• Pancreatic Duct Stricture — all drugs for Pancreatic Duct Stricture →
• Pancreatic Duct Dilatation — all drugs for Pancreatic Duct Dilatation →

Sponsor

Oregon Health and Science University

Who can join

18 and older, any sex, with Pancreatic Duct Stone or Pancreatic Duct Stricture. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Percent Change in Average Daily Pain Score on the Numeric Rating Scale Primary · Day -14 to Day 90

The percent change in average daily pain score from the daily diaries during the 14-day period preceding the 90-day assessment, compared to the average daily pain reported during the 14-day run-in. The investigators employed the standardized 11-point Numeric Rating Scale (NRS) to capture average daily pain with the empirically-supported anchors of 0=No Pain and 10=Worst Pain Imaginable.

Group	Value	95% CI
EUS + SHAM	-36.6	-39.3 – -11.6
EUS + Pancreatic Endotherapy	-53.7	-100.0 – -27.9

Adverse events — posted to ClinicalTrials.gov

Time frame: An Adverse Event form was used to document reportable adverse events (AEs) for this study, which included: 1. All non-serious adverse events related to abdominal pain in addition to all serious adverse events were reported through Day 30 2. All serious adverse events (SAEs) were reported through the end of study (12 months post randomization) 3. All acute pancreatitis events or pancreatitis-related pain events that occur were reported through end of study ((12 months post randomization).. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

EUS + SHAM

Serious: 4/6 (67%)

Deaths: 0/6

EUS + Pancreatic Endotherapy

Serious: 6/8 (75%)

Deaths: 0/8

Serious adverse events (16 terms)

Reaction	System	EUS + SHAM	EUS + Pancreatic Endotherapy
Abdominal pain	Gastrointestinal disorders	—	—
Chronic pancreatitis	Hepatobiliary disorders	—	—
Acute pancreatitis > 30 days from randomization	Hepatobiliary disorders	—	—
Acute pancreatitis within 30 days of randomization	Hepatobiliary disorders	—	—
Acute pain	General disorders	—	—
Post procedural pain	Gastrointestinal disorders	—	—
Active Suicidal Ideation	Psychiatric disorders	—	—
Anaphylaxis	Respiratory, thoracic and mediastinal disorders	—	—
Coronavirus infection	Infections and infestations	—	—
Costochondritis	Musculoskeletal and connective tissue disorders	—	—
Elevated liver enzyme levels	Hepatobiliary disorders	—	—
Hyperglycemia	Endocrine disorders	—	—
Sepsis	Infections and infestations	—	—
Suprapubic pain	Gastrointestinal disorders	—	—
Temporal headache	General disorders	—	—
Urinary tract infection	Infections and infestations	—	—

Other adverse events (1 terms — click to expand)

Reaction	System	EUS + SHAM	EUS + Pancreatic Endotherapy
Abdominal pain	Gastrointestinal disorders	—	—

Most-reported serious reactions: Abdominal pain, Chronic pancreatitis, Acute pancreatitis > 30 days from randomization, Acute pancreatitis within 30 days of randomization, Acute pain, Post procedural pain, Active Suicidal Ideation, Anaphylaxis.

Data from ClinicalTrials.gov NCT04232670 adverse events section.

Sponsor's own description

The purpose of this study is to evaluate whether endoscopic ultrasound (EUS) only versus EUS + endoscopic retrograde cholangiopancreatography (ERCP) with pancreatic endotherapy reduces pain in the treatment of chronic pancreatitis with pancreatic duct obstruction.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Management of chronic pancreatitis: recent advances and future prospects.
   Han C, Lv YW, Hu LH. · · 2024 · cited 5× · PMID 38406795 · DOI 10.1177/17562848241234480
2. Interventions for Pancreatitis-New Approaches, Knowledge Gaps, and Research Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.
   Phillips AE, Hughes SJ, Andersen DK, Bell A, et al · · 2024 · cited 2× · PMID 38518063 · DOI 10.1097/mpa.0000000000002333